MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/btm2.70015

Медицинская библиотека · Bioengineering & translational medicine · 2025

Spatial-hindrance-based pro-Adalimumab prevents anti-idiotypic antibody interference in pharmacokinetic and therapeutic efficacy.

Huang Bo-Cheng, Chen Yu-Tung, Lu Yun-Chi, Ho Kai-Wen, Hong Shih-Ting, Liao Tzu-Yi, Wu I-Hsuan, Liu En-Shuo, Liao Jun-Min, Chen Fang-Ming, Li Chia-Ching, Chuang Chih-Hung, Chen Chiao-Yun, Cheng Tian-Lu

СтатьяПеревод в очереди

Аннотация

Adalimumab (Humira) represents a major advance in rheumatoid arthritis (RA) therapy. However, with long-term administration of Adalimumab, anti-idiotypic antibody (anti-Id Ab) accelerates the Adalimumab clearance rate and reduces the therapeutic effect. To avoid the interference of anti-Id Ab, we used an autologous hinge region as a spatial-hindrance-based Ab lock and connected it to the N-terminal of the light chain and heavy chain via substrate peptides (MMP-2/9) to cover the CDR binding site of Adalimumab to generate pro-Adalimumab. The Ab lock masks the complementarity-determining regions (CDRs) of Adalimumab, thus avoiding interference from anti-Id Ab. Pro-Adalimumab demonstrated a 241.6 times weaker binding ability to TNFɑ than Adalimumab. In addition, pro-Adalimumab showed a 46.6-fold greater blocking of anti-Adalimumab Id Ab in comparison to Adalimumab prior to activation. Similar results were observed with other clinical antibodies, such as pro-Infliximab (anti-TNFɑ Ab) and pro-Nivolumab (anti-PD-1). Furthermore, pro-Adalimumab maintained consistent pharmacokinetics regardless of the presence of anti-Adalimumab Id antibodies, while Adalimumab showed a 49% clearance increase, resulting in a near complete loss of function. Additionally, pro-Adalimumab was able to avoid neutralization and efficiently reduce RA progression in the presence of anti-Adalimumab Id Ab in vivo. In summary, we developed a pro-Adalimumab that avoids interference from anti-Id Abs, thereby addressing the biggest issue limiting clinical efficacy. The findings enclosed herein may have potentially broad application in antibody therapies.

Для цитирования: Huang Bo-Cheng, Chen Yu-Tung, Lu Yun-Chi, Ho Kai-Wen, Hong Shih-Ting, Liao Tzu-Yi, Wu I-Hsuan, Liu En-Shuo, Liao Jun-Min, Chen Fang-Ming, Li Chia-Ching, Chuang Chih-Hung, Chen Chiao-Yun, Cheng Tian-Lu. Spatial-hindrance-based pro-Adalimumab prevents anti-idiotypic antibody interference in pharmacokinetic and therapeutic efficacy.. Bioengineering & translational medicine. 2025. DOI: 10.1002/btm2.70015.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.